OK , don't quote me verbatim
Firstly the Directors, CEO, Board showed up, and after Friday that takes a spine , many other companies could take a leaf out of LCT Book.
Imupell may well be a stand alone product, It has value, it is still the only cell therapy delivery system that does not require lowering the patients immune system. Do I think it could be licensed yes. It is really only protected by propriety knowledge,,trade secret. LCT can produce Imupell for other cell therapies..as a delivery.
The Board removed the entitlement of Options immediately from the vote slip , so again shows scruples and integrity.
The in-depth analysis should only take weeks not Months as was discussed on Friday.
Company have highlighted benefits with regard to Auckland Hospital and Brain Clinic. Positive data..
One year data from patients involved in Phase II Trial , group 1 and 2 December, and Group 3 in May next year.
The Placebo effect should continue to decline beyond the 6 month mark but all patients are different.
Yes , The PR and market awareness needs to be lifted, paid investor content required to broaden the Shareholder base, LCT has roughly 3000 SH, had it had 30,000 you wouldn't have seen the reaction that we encountered on Friday.
I brought up the $120,000,000 wiped off the MC on Friday and reminded LCT they are a company not a research institute.
other shareholders said they wanted to see value attributed to the technology,, whats it worth now, what could it be worth,, whats going to be the return, real dollars,,,return on investment in LCT.
The Gentleman from Diabecell had flown over from Japan and they will be meeting with LCT today and tomorrow , one comment was they are regularly updated but I believe we have all requested further info on progress and told about some confidentially agreement?? They have also invested Millions beyond what LCT could have,,, and have conducted another trial that had ,,,again ,,,promising results in certain patients. One question here was whats the Value,$$,how will LCT garnish a return from Diabecell to benefit Shareholders. The Japanese Co has Japan and the USA as a licensed territory and LCT has the rest of the world.
So to raise additional funds , i would like to suggest LCT sell other territories to the Japanes now,,not all but some,,,$$$$ in the door will be LCT's saviour now.
It was mentioned they've nothing to do a CR against,,as in nothing clear cut to apply funding to..
Yes they know they have $6m AUD which is 500 more than i thought. they know they have to put that in one barrel and shoot it at the best target...
Some Heavy Hitters were at the meeting, one Gentleman had poured in 7 figures, plus i recognized a few faces from the top 20. I think it was Bob that said he lost his retirement apartment also so the company had the same belief as we did.
There is Trial extension Protocol,, it allows LCT to continue to monitor BUT if something was discovered from the Phase II trial , it would only stimulate a ""new trial"" on that discovery LCT can't bring it in under the current Phase II.
They have also put themselves in a tricky spot because if an error was located you could only imagine the class action from shareholders that sold on the poor release last Friday.
I only held enough shares to attend, I sold last Friday... Until i see a clear path ahead and a business model with returns attached to it, i will not be investing..
DYOR and proceed as you see fit..
Expand
